The Medicines Company - Product Pipeline Review - 2016

Published: May, 2016 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

The Medicines Company - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'The Medicines Company - Product Pipeline Review - 2016', provides an overview of the The Medicines Company's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by The Medicines Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of The Medicines Company
- The report provides overview of The Medicines Company including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses The Medicines Company's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features The Medicines Company's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate The Medicines Company's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for The Medicines Company
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding The Medicines Company's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
The Medicines Company Snapshot 6
The Medicines Company Overview 6
Key Information 6
Key Facts 6
The Medicines Company - Research and Development Overview 7
Key Therapeutic Areas 7
The Medicines Company - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
The Medicines Company - Pipeline Products Glance 15
The Medicines Company - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
The Medicines Company - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
The Medicines Company - Early Stage Pipeline Products 19
IND/CTA Filed Products/Combination Treatment Modalities 19
Preclinical Products/Combination Treatment Modalities 20
The Medicines Company - Drug Profiles 21
bivalirudin 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
cangrelor tetrasodium 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
clevidipine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
(meropenem+ vaborbactam [INN]) 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ABP-700 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MDCO-216 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
fentanyl 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
oritavancin diphosphate 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Carboetomidate 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Methoxycarbonyl Carboetomidate 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Methoxycarbonyl Etomidate 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Inhibit Carbapenemase for Bacterial Infections 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
tigecycline 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
The Medicines Company - Pipeline Analysis 41
The Medicines Company - Pipeline Products by Target 41
The Medicines Company - Pipeline Products by Route of Administration 42
The Medicines Company - Pipeline Products by Molecule Type 43
The Medicines Company - Pipeline Products by Mechanism of Action 44
The Medicines Company - Recent Pipeline Updates 45
The Medicines Company - Dormant Projects 55
The Medicines Company - Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables

The Medicines Company, Key Information 6
The Medicines Company, Key Facts 6
The Medicines Company - Pipeline by Indication, 2016 8
The Medicines Company - Pipeline by Stage of Development, 2016 10
The Medicines Company - Monotherapy Products in Pipeline, 2016 11
The Medicines Company - Combination Treatment Modalities in Pipeline, 2016 12
The Medicines Company - Partnered Products in Pipeline, 2016 13
The Medicines Company - Partnered Products/ Combination Treatment Modalities, 2016 14
The Medicines Company - Pre-Registration, 2016 15
The Medicines Company - Phase III, 2016 16
The Medicines Company - Phase II, 2016 17
The Medicines Company - Phase I, 2016 18
The Medicines Company - IND/CTA Filed, 2016 19
The Medicines Company - Preclinical, 2016 20
The Medicines Company - Pipeline by Target, 2016 41
The Medicines Company - Pipeline by Route of Administration, 2016 42
The Medicines Company - Pipeline by Molecule Type, 2016 43
The Medicines Company - Pipeline Products by Mechanism of Action, 2016 44
The Medicines Company - Recent Pipeline Updates, 2016 45
The Medicines Company - Dormant Developmental Projects,2016 55
The Medicines Company, Other Locations 56
The Medicines Company, Subsidiaries 57